Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Short Interest Up 34.3% in December

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 46,799 shares, an increase of 34.3% from the November 30th total of 34,835 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average daily volume of 62,901 shares, the short-interest ratio is currently 0.7 days. Based on an average daily volume of 62,901 shares, the short-interest ratio is currently 0.7 days. Approximately 0.6% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

BNR has been the subject of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Burning Rock Biotech Price Performance

Shares of BNR stock opened at $20.58 on Tuesday. The stock’s fifty day simple moving average is $16.26 and its 200 day simple moving average is $10.19. Burning Rock Biotech has a one year low of $2.18 and a one year high of $24.18. The firm has a market cap of $221.44 million, a price-to-earnings ratio of -12.40 and a beta of 1.19. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.14 and a quick ratio of 2.91.

Institutional Investors Weigh In On Burning Rock Biotech

Several large investors have recently made changes to their positions in the company. Crcm LP increased its position in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Burning Rock Biotech during the third quarter worth about $26,000. Finally, Prospera Financial Services Inc acquired a new stake in shares of Burning Rock Biotech during the third quarter worth approximately $214,000. Institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.